RGD Reference Report - TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior.

Authors: Ivanov, S V  Panaccione, A  Brown, B  Guo, Y  Moskaluk, C A  Wick, M J  Brown, J L  Ivanova, A V  Issaeva, N  El-Naggar, A K  Yarbrough, W G 
Citation: Ivanov SV, etal., Oncogene. 2013 Aug 8;32(32):3698-710. doi: 10.1038/onc.2012.377. Epub 2012 Oct 1.
RGD ID: 150519921
Pubmed: PMID:23027130   (View Abstract at PubMed)
DOI: DOI:10.1038/onc.2012.377   (Journal Full-text)

Treatment options for adenoid cystic carcinoma (ACC) of the salivary gland, a slowly growing tumor with propensity for neuroinvasion and late recurrence, are limited to surgery and radiotherapy. Based on expression analysis performed on clinical specimens of salivary cancers, we identified in ACC expression of the neurotrophin-3 receptor TrkC/NTRK3, neural crest marker SOX10, and other neurologic genes. Here, we characterize TrkC as a novel ACC marker, which was highly expressed in 17 out of 18 ACC primary-tumor specimens, but not in mucoepidermoid salivary carcinomas or head and neck squamous cell carcinoma. Expression of the TrkC ligand NT-3 and Tyr-phosphorylation of TrkC detected in our study suggested the existence of an autocrine signaling loop in ACC with potential therapeutic significance. NT-3 stimulation of U2OS cells with ectopic TrkC expression triggered TrkC phosphorylation and resulted in Ras, Erk 1/2 and Akt activation, as well as VEGFR1 phosphorylation. Without NT-3, TrkC remained unphosphorylated, stimulated accumulation of phospho-p53 and had opposite effects on p-Akt and p-Erk 1/2. NT-3 promoted motility, migration, invasion, soft-agar colony growth and cytoskeleton restructuring in TrkC-expressing U2OS cells. Immunohistochemical analysis demonstrated that TrkC-positive ACC specimens also show high expression of Bcl2, a Trk target regulated via Erk 1/2, in agreement with activation of the TrkC pathway in real tumors. In normal salivary gland tissue, both TrkC and Bcl2 were expressed in myoepithelial cells, suggesting a principal role for this cell lineage in the ACC origin and progression. Sub-micromolar concentrations of a novel potent Trk inhibitor AZD7451 completely blocked TrkC activation and associated tumorigenic behaviors. Pre-clinical studies on ACC tumors engrafted in mice showed efficacy and low toxicity of AZD7451, validating our in vitro data and stimulating more research into its clinical application. In summary, we describe in ACC a previously unrecognized pro-survival neurotrophin signaling pathway and link it with cancer progression.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
NTRK3Humanadenoid cystic carcinoma treatmentIMP  RGD 
Ntrk3Ratadenoid cystic carcinoma treatmentISONTRK3 (Homo sapiens) RGD 
Ntrk3Mouseadenoid cystic carcinoma treatmentISONTRK3 (Homo sapiens) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ntrk3  (neurotrophic receptor tyrosine kinase 3)

Genes (Mus musculus)
Ntrk3  (neurotrophic tyrosine kinase, receptor, type 3)

Genes (Homo sapiens)
NTRK3  (neurotrophic receptor tyrosine kinase 3)


Additional Information